Celltrion068270.KS
About Celltrion
Celltrion is a biopharmaceutical company best known for biosimilars, near-copies of complex biologic drugs whose patents have expired. It developed one of the world's first approved antibody biosimilars and has built a portfolio spanning treatments for autoimmune diseases, cancer, and other conditions, sold in the United States, Europe, and other markets. Following the absorption of its distribution affiliate Celltrion Healthcare, the company handles both development, manufacturing at its Incheon plants, and overseas sales within a single listed entity. It is also pushing into novel-drug research and subcutaneous reformulations of existing products to extend franchise life.
Unlike most large Korean issuers, Celltrion is founder-led rather than part of a traditional chaebol, so governance debate has centered on transactions among affiliated companies and the long-mooted consolidation of the wider group structure. Revenue is overwhelmingly generated abroad, tying results to drug-pricing dynamics and reimbursement rules in the United States and Europe. Each product faces a defined competitive window as rival biosimilars launch, making pipeline replenishment a structural necessity. The stock carries a large weight in Korean health-care benchmarks, tends to trade on clinical and regulatory milestones, and has historically attracted heavy domestic retail participation.
Celltrion was founded in 2002 by entrepreneur Seo Jung-jin, a former Daewoo executive who bet on biologics manufacturing in Incheon before biosimilars were an established industry. The company initially made drugs under contract for multinationals, then pivoted to developing its own biosimilars, gaining European approval for a pioneering antibody biosimilar in 2013. For years the group operated through a split structure, with Celltrion manufacturing products and separately listed Celltrion Healthcare selling them abroad, an arrangement long criticized for opacity; the two merged at the end of 2023, uniting production and distribution. A third affiliate handles chemical drugs in the domestic market.
Revenue flows from selling finished biosimilars to hospital systems, pharmacy chains, and wholesalers in Europe, the United States, and other markets, increasingly through the company's own direct-sales subsidiaries rather than third-party partners, a shift that captures distribution margin. Winning tenders and formulary placements is the core commercial mechanic, since biosimilars compete chiefly on price and reliability of supply against both originator drugs and rival copies. In-house manufacturing at scale underpins cost competitiveness, and newer differentiated products, such as subcutaneous reformulations with regulatory exclusivities, earn better pricing than plain copies. Export markets supply the great bulk of sales, making reimbursement policy abroad the key external variable.
Company profile by LineVest editorial. Journalism, not investment advice. Commission a full DART-based report on Celltrion →
Celltrion coverage
16 articles
Celltrion (068270.KS): Q2 Op Profit Up 77%, Shares Down 20%
Celltrion (068270.KS), South Korea's largest biosimilar maker, reported preliminary second-quarter 2026 results on July 3 showing operating profit up 77.3% to ₩
Samsung, SK Hynix and Celltrion Pledge KRW 392 Trillion to Chungcheong in Korea's 'Second Tokyo Declaration'
Samsung, SK Hynix CEO Kwak No-jeong and Celltrion commit KRW 392 trillion to Chungcheong as President Lee calls it Korea's 'second Tokyo Declaration.' Anthropic also eyes Samsung 2nm foundry.
Celltrion (068270.KS) Q2: Margin 33%, Record ₩430B Profit
Celltrion (068270.KS), Korea's largest biosimilar maker, said its second-quarter operating margin leapt to roughly 33% — the sharpest profitability move in the
Celltrion Remsima SC Commands 31% EU5 Market Share as Phase 3 Crohn's Data Affirms 44-Week Efficacy
Celltrion presented 44-week Remsima SC Phase 3 Crohn's data at AOCC&IMKASID 2026 in Seoul. The subcutaneous biosimilar holds a 31% EU5 market share in Q4 2025 and US Zimpetra prescriptions tripled in Q1 2026 year-on-year.
Korea Unveils First-Ever 'Korea Rising' Session at BIO 2026 as Celltrion Bets on AI-Drug Pivot and ABL Bio Eyes Global Licensing
Korea debuts 'Korea Rising' session at BIO 2026 as Celltrion pivots to AI drugs and ABL Bio seeks global licensing deals, while KB Investment warns Korean biotechs to form US subsidiaries to access institutional capital.
U.S. Poised to Scrap Biosimilar’s ‘Interchangeable’ Hurdle — Celltrion and Samsung Bioepis Stand to Gain Most
The bipartisan Biosimilar Red Tape Elimination Act (S.1954) and parallel FDA guidance would cut Korean drug makers’ development costs 70–90% and shorten timelines by up to four years.
Celltrion Adds Two Cancer Biosimilars in Vietnam
Celltrion is widening its footprint in Vietnam, a small but fast-growing Southeast Asian market — a move that tells investors more about strategy than about this quarter's revenue.
Celltrion Touts HER2 Bispecific Cancer Data, Eyes FDA Fast-Track in 2026
Celltrion (068270.KS), one of South Korea's two largest biopharmaceutical companies by revenue alongside Samsung Biologics and best known for biosimil
Celltrion (068270.KS) Nears ₩2 Trillion Cancellation Goal
Celltrion's First-Ever Union Lands as Record Margins Peak
Celltrion (068270.KS), the Incheon-based biosimilar maker that is South Korea's largest by sales, saw workers form the first labor union in its history on June 1, ending a no-union stretch that has held since the company's 2002 founding (Yonhap; Korea Times). The timing is what matters to investors: the union arrives weeks after Celltrion booked the most profitable year it has ever reported.
Samsung Bio Strike Hardens; Celltrion Forms First Union
Celltrion (068270.KS), South Korea's largest biosimilar developer, said its workers launched a labor union on June 1 — the first in the company's history since founder Seo Jung-jin started it in 2002, according to Chosun Biz and The Korea Times. The move lands as a separate dispute at Samsung Biolog
Celltrion (068270.KS) Adds ₩200B to 2026 Buyback as 0.05 Bonus Issue Sets June Listing
Celltrion added a ₩100B treasury buyback plus a ₩100B parent purchase on May 21, lifting 2026 cancellations toward ~₩2T as a 0.05 bonus issue lists 10.92M shares.
Celltrion (068270.KS) Buys France's Gifrer to Tap 9,000 Pharmacies
Celltrion (068270.KS), Korea's largest biosimilar maker, said on May 12 it has acquired 100% of Gifrer, a 1912-founded French over-the-counter (OTC) and pharmacy pro
Celltrion (068270.KS) Q1 Profit Doubles on Biosimilar Surge
Celltrion's Q1 operating profit more than doubled to 321.9 billion won as biosimilar sales drove revenue up 28% to a record 1.145 trillion won.
Biosimilar M&A Tests Celltrion (068270.KS), Samsung Bioepis
Celltrion Launches Tocilizumab Biosimilar Avtozma in Japan, Expanding Autoimmune Portfolio to Four
Frequently asked questions
What does Celltrion do?
Celltrion is a South Korean biopharmaceutical company that develops and manufactures biosimilars, near-copies of complex biologic drugs whose patents have expired, treating autoimmune diseases, cancers, and other conditions. It produces at large plants in Incheon and sells worldwide, while also developing novel drugs and improved formulations of existing products.
Who controls Celltrion?
Founder Seo Jung-jin controls the company through Celltrion Holdings, the family holding vehicle that is the largest shareholder. Unlike most major Korean issuers, Celltrion is not part of a traditional conglomerate; beyond the founder's stake, ownership is spread across institutions and an unusually large domestic retail shareholder base.
How can foreign investors get exposure to Celltrion?
Celltrion trades on the Korea Exchange under ticker 068270 and carries a heavy weight in Korean health-care indexes. It has no overseas depositary receipts, so access is typically through brokers offering Korean market trading or through Korea-focused and biotech-oriented ETFs that hold the Seoul-listed shares.
Answers are editorial summaries for general information, not investment advice.
Go deeper than the headline
You just read what happened. Here's how to read what it means.
The Korean market week, in one email
Every Saturday: the week's key KOSPI & KOSDAQ stories, earnings and foreign flows — picked from our daily coverage. Free, no card required.
Want it every morning before the open? LineVest Daily — $2.99/mo →
Full report on Celltrion
We read Celltrion's latest DART filing in full — financials under K-IFRS, governance, and what it means for the stock. PDF in your inbox within 3 hours.
$12 · one-time
Get the Celltrion reportFollow the whole market
Reading several Korean stocks a week? Read every analysis article the moment it publishes — full daily KOSPI & KOSDAQ coverage plus the 90-day archive.
$9.99 · monthly
SubscribeIndependent journalism based on primary DART filings — not investment advice. No brokerage affiliation.